Fig 2: Mean (SD) plasma anti-FXa (A) and anti-FIIa (B) activity, and baseline-adjusted TFPI levels (C) versus time curves (linear scale) after fasting of single doses of the test or reference drug.Notes: Test drug is enoxaparin sodium 100 mg (10,000 IU anti-FXa/1.0 mL) manufactured by Rovi, Madrid, Spain (●). Reference drug is enoxaparin sodium 100 mg (Clexane® 10,000 IU anti-FXa/1.0 mL) manufactured by Sanofi, Maison Alfort, France (■). Data shown from PK/PD analysis set (n=43).Abbreviations: PD, pharmacodynamic; PK, pharmacokinetic; SC, subcutaneous; TFPI, tissue factor pathway inhibitor.

Fig 3: The expression levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in equal volumes (15 µl) of vitreous fluid samples obtained from patients with proliferative diabetic retinopathy (PDR; n=12) and from control patients without diabetes (RD; n=12) were determined with Western blot analysis. A representative set of samples is shown. The resultant data are presented in the histograms as mean ± standard deviation. The expressions of TF (A) and both intact and cleaved TFPI (B) are significantly increased in vitreous samples from PDR patients compared to control patients without diabetes. *The difference between the two means was statistically significant at the 5% level of significance (p=0.0001; p=0.0001; p=0.01, respectively; Mann-Whitney test).